Cryptic Pockets Expand the Druggable Space of Natural Product Pharmacology Through Conformational Sampling, Transient Site Detection, and Structure-Guided Ligand Discovery

Download PDF

Static protein structures can conceal ligand-binding opportunities that emerge only when conformational fluctuations expose otherwise inaccessible regions. Cryptic pockets therefore challenge structure-centered definitions of druggability, but their discovery creates a second problem: transient-site detection is not equivalent to ligandability, functional relevance, or pharmacological usefulness. This conceptual framework integrates protein dynamics, molecular simulation, experimental hidden-state evidence, natural-product chemical-space reasoning, and structure-guided ligand discovery into an evidence-bounded strategy for cryptic-pocket pharmacology. The analysis distinguishes cryptic pockets from merely small or shallow cavities, separates pocket opening from persistence and druggability, and treats computational detection as an evidence-generating step rather than structural confirmation. It further proposes that the stereochemical and three-dimensional complexity represented in natural-product and natural-product-like chemical space may complement some conformationally generated binding environments, while emphasizing that preferential cryptic-pocket recognition by natural products has not been demonstrated. The principal contribution is a proposed pocket-before-ligand framework in which candidate sites are prioritized according to evidence for accessible opening, recurrence, structural and physicochemical coherence, functional connectivity, and orthogonal validation before ligand ranking is allowed to dominate. The framework also separates docking plausibility, target engagement, functional modulation, allosteric interpretation, and downstream pharmacology. Major boundaries include rare-state sampling, force-field and model dependence, uncertain opening probabilities, incomplete experimental observability, and sparse direct evidence connecting natural-product shape complexity to cryptic-site preference. Cryptic pockets expand actionable structural space only when dynamic detectability is converted into experimentally constrained pharmacological opportunity.